USFDA9 Jul 2025, 05:32 pm
Emcure Pharmaceuticals Ltd. Receives Zero Observations in US FDA Inspection at Oncology Facility
AI Summary
Emcure Pharmaceuticals Ltd. has announced that the United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) of the company's manufacturing facility located at Sanand, Ahmedabad, Gujarat, India, from June 30, 2025, to July 08, 2025. The inspection concluded without any observations or issuance of Form 483, indicating zero observations. This is a significant development, highlighting the company's commitment to maintaining high standards of quality and compliance at its manufacturing facilities.
Key Highlights
- US FDA conducted a Pre-Approval Inspection (PAI) at Emcure Pharmaceuticals Ltd.'s manufacturing facility located at Sanand, Ahmedabad, Gujarat, India.
- The inspection concluded without any observations or issuance of Form 483, indicating zero observations.
- This development highlights Emcure Pharmaceuticals Ltd.'s commitment to maintaining high standards of quality and compliance.